Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Geoffrey Kempler
Date of Last Notice:	04 August 2009

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	Direct		
Nature of indirect interest (including registered holder)	-			
Date of change	31 October 20	31 October 2010		
No. of securities held prior to change		Shares	Options	
	Direct	30,000	2,000,000	
	Indirect	17,025,000	-	
	Total	17,055,000	2,000,000	
Class	Options			
Number acquired		Shares	Options	
	Direct		-	
	Indirect	-	-	
	Total	-	-	
Number disposed				
Number disposed		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	_	
		·	<u></u>	

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL		
No. of securities held after change		Shares	Options
	Direct	30,000	-*
	Indirect	17,025,000	-
	Total	17,055,000	_*
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		has been adjus ns on 31 Octobe	ted for expiry of er 2010.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to	
which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	



The CFO Solution

03.11.2010

Rule 3.19A.2

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	George Mihaly
Date of Last Notice:	04 August 2009

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct	Direct		
Nature of indirect interest (including registered holder)	-			
Date of change	31 October 20	31 October 2010		
No. of securities held prior to change		Shares	Options	
	Direct	166,666	650,000	
	Indirect	60,000	-	
	Total	226,666	650,000	
			_	
Class	Options			
Number acquired		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	
Number disposed				
Number disposed		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL		
No. of securities held after change		Shares	Options
	Direct	166,666	_*
	Indirect	60,000	-
	Total	226,666	_*
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		has been adjust ns on 31 Octobe	red for expiry of at 2010.

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to	
which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	



The CFO Solution

03.11.2010

Rule 3.19A.2

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Brian Meltzer
Date of Last Notice:	04 August 2009

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect			
Nature of indirect interest (including registered holder)	-			
Date of change	31 October 20	31 October 2010		
No. of securities held prior to change		Shares	Options	
	Direct	-	-	
	Indirect	326,666	650,000	
	Total	326,666	650,000	
Class	Options			
Number acquired		Shares	Options	
	Direct	-	_	
	Indirect	-	-	
	Total	-	-	
Number dispessed	<u> </u>			
Number disposed		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	
		•		

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL			
No. of securities held after change		Shares	Options]
	Direct	-	-	
	Indirect	326,666	_*]
	Total	326,666	_*	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	of end PBTAG Options on 31 October 2010.		of	

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to	
which interest related prior to	
change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	



The CFO Solution

03.11.2010

Rule 3.19A.2

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Peter Marks
Date of Last Notice:	04 August 2009

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct			
Nature of indirect interest (including registered holder)	-			
Date of change	31 October 20	31 October 2010		
No. of securities held prior to change		Shares	Options	
	Direct	-	350,000	
	Indirect	43,111	300,000	
	Total	43,111	650,000	
Class	Options			
Number acquired		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	
Number disposed				
Number disposed		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL		
No. of securities held after change		Shares	Options
	Direct	-	_*
	Indirect	43,111	_*
	Total	43,111	_*
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	of PBTAG Options on 31 October 2010.		1 0

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	



The CFO Solution

03.11.2010

Rule 3.19A.2

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of Entity:	Prana Biotechnology Limited
ACN:	080 699 065

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Marks
Date of Last Notice:	14 January 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect			
Nature of indirect interest (including registered holder)	-			
Date of change	31 October 20	31 October 2010		
No. of securities held prior to change		Shares	Options	
	Direct	-	-	
	Indirect	8,589,361	701,754	
	Total	8,589,361	701,754	
Class	Options			
Number acquired		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	
Number disposed				
Number disposed		Shares	Options	
	Direct	-	-	
	Indirect	-	-	
	Total	-	-	

⁺ See chapter 19 for defined terms.

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	NIL			
No. of securities held after change		Shares	Options	
	Direct	-	-	
	Indirect	8,589,361	350,877*	
	Total	8,589,361	350,877*	
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	of PBTAZ Options on 31 October 2010.		of	

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	



The CFO Solution

03.11.2010

Rule 3.19A.2

⁺ See chapter 19 for defined terms.